SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial | 2026-09-03 | Open-market sell 10b5-1 | 1131 | $970K |
| Guarini Kathryn | Director | 2026-09-02 | Option exercise 10b5-1 | 400 | $288K |
| Guarini Kathryn | Director | 2026-09-02 | Open-market sell 10b5-1 | 400 | $340K |
| McCourt Marion | EVP Commercial | 2026-09-02 | Open-market sell 10b5-1 | 1215 | $1.0M |
| LAROSA JOSEPH J | EVP General Counsel and Secret | 2026-08-19 | Option exercise | 12282 | $4.7M |
| LAROSA JOSEPH J | EVP General Counsel and Secret | 2026-08-19 | Tax withholding | 9019 | $7.5M |
| Fenimore Christopher R. | EVP Finance CFO | 2026-08-18 | Option exercise | 6283 | $2.4M |
| Fenimore Christopher R. | EVP Finance CFO | 2026-08-18 | Tax withholding | 4599 | $3.7M |
| Guarini Kathryn | Director | 2026-08-10 | Option exercise 10b5-1 | 400 | $288K |
| Guarini Kathryn | Director | 2026-08-10 | Open-market sell 10b5-1 | 400 | $320K |
| Zoghbi Huda Y | Director | 2026-08-10 | Option exercise 10b5-1 | 800 | $301K |
| Zoghbi Huda Y | Director | 2026-08-10 | Open-market sell 10b5-1 | 800 | $640K |
| RYAN ARTHUR F | Director | 2026-07-02 | Open-market sell 10b5-1 | 200 | $130K |
| RYAN ARTHUR F | Director | 2026-05-01 | Open-market sell 10b5-1 | 5 | $4K |
| RYAN ARTHUR F | Director | 2026-05-01 | Open-market sell 10b5-1 | 15 | $11K |
| RYAN ARTHUR F | Director | 2026-05-01 | Open-market sell 10b5-1 | 24 | $17K |
| RYAN ARTHUR F | Director | 2026-05-01 | Open-market sell 10b5-1 | 15 | $11K |
| RYAN ARTHUR F | Director | 2026-05-01 | Open-market sell 10b5-1 | 14 | $10K |
| RYAN ARTHUR F | Director | 2026-05-01 | Open-market sell 10b5-1 | 7 | $5K |
| RYAN ARTHUR F | Director | 2026-05-01 | Open-market sell 10b5-1 | 4 | $3K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Regeneron faces a broad, simultaneous deterioration across regulatory, competitive, operational, and macro dimensions — the most concentrated risk escalation is in the regulatory/policy arena, where executive-branch drug pricing directives (including a direct presidential request), MFN pricing mandates, pharmaceutical importation orders, DTC advertising reform, FDA staffing/budget cuts, and a new tax law all materialized in a single filing cycle. Compounding this, EYLEA faces realized revenue pressure from compounded bevacizumab competition and a CRL for the HD pre-filled syringe, while a Phase 3 COPD failure for itepekimab and a pattern of multiple CRLs signal broader pipeline execution risk. New tariff exposure, a multi-year ERP implementation, expanded manufacturing requirements for novel modalities, and independent EU commercialization launches add operational and financial complexity that was not previously disclosed.
7 company-specific · 8 common-mode
FDA issued October 2025 CRL for EYLEA HD pre-filled syringe, delaying approval. Concrete regulatory setback escalates risk from generic to specific, material product approval delay.
Many of our products are intended to be used and, if approved, our product candidates may be used in combination with drug-delivery devices, which may result in additional regulatory…
Added specific disclosure of EYLEA market share loss to compounded bevacizumab due to patient affordability constraints, demonstrating realized adverse impact on revenues.
Sales of our marketed products are dependent on the availability and extent of coverage and reimbursement and copay assistance from third-party payors and other third parties. Sales of our marketed…
Added concrete example: May 2025 itepekimab Phase 3 trial failure in COPD. Demonstrates realized clinical setback, not hypothetical risk. Also added FDA personnel change risk.
Successful development of our current and future product candidates is uncertain. Only a small minority of all research and development programs ultimately result in commercially successful drugs.…
Multiple CRLs now disclosed as recent and ongoing, escalating from single linvoseltamab example to broader pattern affecting multiple products/candidates.
Our or our collaborators' or contract manufacturers' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in…
New disclosure of multi-year ERP system implementation with material operational risks, end-of-life hardware/software vulnerabilities, and explicit business continuity/disaster recovery concerns.
Significant disruptions of information technology systems or breaches of data security could adversely affect our business. Our business is increasingly dependent on critical, complex, and…
Added disclosure of need to develop/acquire new manufacturing and distribution capabilities for emerging technology platforms (siRNA, genome editing, viral gene delivery), signaling expanded operational complexity and investment requirements.
We may be unsuccessful in continuing the commercialization of our marketed products or in commercializing our product candidates or new indications for our marketed products, if approved, which would…
Company now explicitly discloses independent commercialization of new products (Lynozyfic, Ordspono) in EU, escalating execution risk and capital requirements beyond prior co-commercialization focus.
If we are unable to establish sufficient commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business…
New executive orders and MFN pricing directives from current administration materially escalate drug pricing pressure beyond prior IRA framework, with direct presidential request to Regeneron.
Product reimbursement and coverage policies and practices, pricing regulations and requirements, and our pricing strategy could change due to various factors beyond our control, which may adversely…
New disclosure of material tariff and trade risks. Pharmaceutical company faces direct exposure to U.S. baseline/reciprocal tariffs on raw materials, potential Section 232 duties, and retaliatory measures. Concrete operational and cost impacts.
We face risks associated with tariffs and other trade restrictions, which may have a material adverse impact on our results of operations and financial condition. Our Company faces risks associated…
New disclosure of Chinese biotech/pharma competition threat; escalated competitive risk from state-backed enterprises in both marketed products and pipeline.
The commercial success of our products and product candidates is subject to significant competition. Marketed Products We face substantial competition from pharmaceutical and biotechnology companies.…
Added reference to April 2025 executive order directing HHS to facilitate pharmaceutical importation at state level, escalating regulatory risk from proposal to active government action.
Sales of our marketed products recorded by us and our collaborators could be reduced by imports from countries where such products may be available at lower prices. Our sales of products we…
New disclosure of FDA staffing/budget cuts and government shutdown risks materially impacting regulatory review timelines and approval capacity. Multiple recent CRLs from manufacturing inspections now disclosed.
Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products Obtaining and…
New disclosure of current administration's DTC advertising reform initiative with expanded FDA oversight and enforcement, creating heightened regulatory risk and compliance burden.
Our business activities have been, and may in the future be, challenged under U.S. federal or state and foreign healthcare laws, which may subject us to civil or criminal proceedings, investigations…
Added specific disclosure of current U.S. administration's active drug cost-reduction measures and new FDA budget/workforce reduction risks affecting regulatory review timelines.
Changes in laws, regulations, and policies affecting the healthcare industry could adversely affect our business. All aspects of our business, including research and development, manufacturing…
New reference to "One Big Beautiful Bill Act" (July 2025) with cross-reference to financial statement note suggests material tax law change requiring disclosure and analysis.
We may incur additional tax liabilities related to our operations. We are subject to income tax in the United States and foreign jurisdictions in which we operate. Significant judgment is required in…
This is a clear earnings release disclosing Regeneron's financial and operating results for Q2 2026. The press release, furnished as Exhibit 99.1 to Item 2.02, reports quarterly revenues of $4.3 billion (17% increase), GAAP EPS of $12.23, non-GAAP EPS of $14.29, and provides detailed product sales performance and 2026 financial guidance. This is a standard quarterly earnings disclosure material to investors.
View raw filing on EDGAR →This Item 2.02 disclosure provides preliminary financial results for Q2 2026, specifically flagging an expected acquired IPR&D charge of approximately $127 million that will negatively impact both GAAP and non-GAAP net income per diluted share by approximately $1.00. While the full earnings release is not attached, the disclosure of preliminary quarterly financial results and their expected impact on per-share metrics is characteristic of an earnings-related disclosure under Item 2.02, even though the company notes results have not been finalized.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of Regeneron's 2026 Annual Meeting of Shareholders held on June 12, 2026, including voting outcomes for three proposals: election of Class II directors (five nominees), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →